Phapros Tbk PT Market Cap ($12.99 Million)
Market Cap & Net Worth: Phapros Tbk PT (PEHA)
Phapros Tbk PT market cap. Phapros Tbk PT (JK:PEHA) has a market capitalization of $12.99 Million (Rp221.76 Billion) as of November 7, 2026. Listed on the JK stock exchange, this Indonesia-based company holds position #26234 globally and #567 in its home market, demonstrating a 3.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Phapros Tbk PT's stock price Rp264.00 by its total outstanding shares 840000000 (840.00 Million). Also see PEHA cash flow conversion for how efficiently the company converts equity into cash flow.
Phapros Tbk PT Market Cap History (2018–2026)
Phapros Tbk PT market cap history from 2018 to 2026. Data shows change from $118.09 Million to $12.99 Million (-20.06% CAGR). Check PEHA stock price and chart for real-time trading data and today's change.
Index Memberships
Phapros Tbk PT is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Jakarta Stock Exchange Composite Index
JKSE
|
$405.73 Billion | 0.00% | #553 of 864 |
Weight: Phapros Tbk PT's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Phapros Tbk PT Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Phapros Tbk PT's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Phapros Tbk PT annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Phapros Tbk PT's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Phapros Tbk PT's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $118.09 Million | $1.02 Trillion | $132.31 Billion | 0.00x | 0.00x |
| 2019 | $47.17 Million | $1.11 Trillion | $102.03 Billion | 0.00x | 0.00x |
| 2020 | $79.58 Million | $980.56 Billion | $48.49 Billion | 0.00x | 0.00x |
| 2021 | $52.90 Million | $1.05 Trillion | $11.07 Billion | 0.00x | 0.00x |
| 2022 | $33.05 Million | $1.17 Trillion | $28.07 Billion | 0.00x | 0.00x |
| 2023 | $31.50 Million | $1.01 Trillion | $5.96 Billion | 0.00x | 0.01x |
| 2024 | $15.95 Million | $744.69 Billion | -$285.07 Billion | 0.00x | N/A |
| 2025 | $14.77 Million | $940.88 Billion | $28.03 Billion | 0.00x | 0.00x |
Competitor Companies of PEHA by Market Capitalization
Companies near Phapros Tbk PT in the global market cap rankings as of November 7, 2026. Also see Phapros Tbk PT total assets for a full breakdown of the balance sheet.
Key companies related to Phapros Tbk PT by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Phapros Tbk PT (2018–2026)
Market capitalization of Phapros Tbk PT from 2018 to today. Between 2018 and today, Phapros Tbk PT's market cap moved from $118.09 Million to $ 12.99 Million, with a yearly change of -20.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rp12.99 Million | -12.00% |
| 2025 | Rp14.77 Million | -7.41% |
| 2024 | Rp15.95 Million | -49.38% |
| 2023 | Rp31.50 Million | -4.70% |
| 2022 | Rp33.05 Million | -37.52% |
| 2021 | Rp52.90 Million | -33.52% |
| 2020 | Rp79.58 Million | +68.71% |
| 2019 | Rp47.17 Million | -60.06% |
| 2018 | Rp118.09 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Phapros Tbk PT was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.99 Million USD |
| MoneyControl | $12.99 Million USD |
| MarketWatch | $12.99 Million USD |
| marketcap.company | $12.99 Million USD |
| Reuters | $12.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more